GeoVax Labs, Inc. raises $3.0M Private Placement (United States, May 2026)

GeoVax Announces $3 Million Private Placement Financing Priced At-the-Market Under Nasdaq Rules - TradingView

GeoVax Labs, Inc. is a clinical-stage biotechnology company focused on developing vaccines and immunotherapies for high-consequence infectious diseases and solid tumor cancers. The company is notable for its expedited regulatory pathway for its GEO-MVA vaccine targeting mpox and smallpox, with plans for a pivotal Phase 3 clinical trial in 2026.

GeoVax Announces $3 Million Private Placement Financing Priced At-the-Market Under Nasdaq Rules  TradingView